- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07557303
Stöd för samtycke i rätt tid vid prenatal screening: INFORM-studien
This clinical trial is about prenatal genetic screening. It will test an intervention to help people make decisions about screening. The intervention is a short set of information cards about screening. This intervention is for pregnant participants. They will use the intervention on their mobile phone before they see their doctor.
The study has one main question:
- Do participants who use the intervention feel more confident when they make a decision about screening?
Researchers will compare participants who use the intervention to participants who do not. All participants will have their usual care when they visit their doctor.
What will participants do?
- Participants must be pregnant. They will sign up for the study before their first doctor's visit for their pregnancy. This is the visit where their doctor usually talks with them about screening.
- Some participants will use the intervention before their first doctor's visit. Other participants will not use it.
- All participants will talk with a researcher on the phone after their first doctor's visit.
- Participants who use the intervention will answer a short survey on their phone.
- A few participants who use the intervention will talk with a researcher a second time on the phone.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Sabina Rubeck, MPH
- Telefonnummer: 216-368-2547
- E-post: sabina.rubeck@case.edu
Studera Kontakt Backup
- Namn: Harlie Custer, MA, MPH
- Telefonnummer: (216) 368-5914
- E-post: harlie.custer@case.edu
Studieorter
-
-
California
-
San Francisco, California, Förenta staterna, 94158
- Rekrytering
- Zuckerberg Chan San Francisco General Hospital
-
Kontakt:
- Kimberly Coleman-Phox, MPH
- Telefonnummer: 415-476-6406
- E-post: kimberly.coleman-phox@ucsf.edu
-
Kontakt:
- Miriam Kuppermann, MPH, PhD
- Telefonnummer: 415-502-4089
- E-post: miriam.kuppermann@ucsf.edu
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32209
- Rekrytering
- University of Florida Health
-
Kontakt:
- Niamh Condon, DO, FACOOG
- Telefonnummer: 904-383-1037
- E-post: Niamh.Condon@jax.ufl.edu
-
Kontakt:
- Julie Nowak
- E-post: julie.nowak@jax.ufl.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- Rekrytering
- University of North Carolina
-
Kontakt:
- Neeta Vora, MD
- Telefonnummer: (984) 974-2131
- E-post: Neeta_vora@med.unc.edu
-
Kontakt:
- Amber Ivins, MSCR
- E-post: amber_ivins@med.unc.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Currently pregnant and receiving care at a participating collaborative site - University of North Carolina, Chapel Hill; Zuckerberg Chan San Francisco General Hospital; University of Florida Health, Jacksonville.
- 18 years of age and older
- Able to read, speak, and understand English or Spanish
- Has not previously been offered prenatal genetic screening for the current pregnancy
- 24 weeks (6 months) gestational age or less
Exclusion Criteria:
- Not pregnant, not a patient at a partner clinical site
- Younger than 18 years of age
- Not being able to read, speak, and understand English or Spanish
- Has previously been offered prenatal genetic screening for the current pregnancy
- Greater than 24 weeks gestational age (6 months)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Mobile-based Educational Intervention
Participants in the intervention arm will access a mobile-based educational tool that provides concise, culturally appropriate information about prenatal genetic screening prior to their clinical visit. Immediately after viewing the intervention, participants will complete an online, 6-question acceptability survey. Participants will then complete a one-time structured quantitative telephone interview within one hundred sixty-eight hours (seven days) of their clinician visit to assess their experience with the intervention and to measure decisional self-efficacy. A select subset of participants will participate in an additional qualitative telephone interview to assess the efficacy and usability of the intervention. |
A mobile-based informational tool that participants will access through a Quick Response (QR) code prior to the clinical encounter in which they will be offered prenatal genetic screening. This tool will provide clear and concise information about prenatal genetic screening to support pregnant participants in making an informed decision. |
|
Inget ingripande: Standard of Care
Participants in the standard-of-care arm will receive routine clinical care, including the usual information and counseling provided by clinicians regarding prenatal genetic screening. Participants will complete a one-time structured quantitative telephone interview within one hundred sixty-eight hours (seven days) of their clinician visit to assess their experience being offered prenatal genetic screening and measure decisional self-efficacy. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Decision Self-Efficacy
Tidsram: The scale is completed up to 168-hours (7 calendar days) post-prenatal screening visit.
|
Decision self-efficacy is measured using a slightly adapted version of the "Decision Self-Efficacy Scale" developed by A. O'Connor and colleagues at the Ottawa Hospital Research Institute and is available at https://decisionaid.ohri.ca. The scale contains eleven questions about a patient's decision-making process. The scale was adapted to ask questions about the context of prenatal genetic screening and utilizes a three-point response scale. Response choices and corresponding point values are: "A lot confident (4), a little confident (2), and not confident (0)". The values from each response are summed, divided by 11 and multiplied by 100 to give a score range from 0 to 100. Zero indicates no confidence and 100 indicates extreme confidence. A researcher administers the scale over the phone, once to each participant, within 168-hours after the medical appointment where participants are offered prenatal genetic screening. It should take no more than 5-10 minutes to complete. |
The scale is completed up to 168-hours (7 calendar days) post-prenatal screening visit.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Marsha Michie, PhD, Case Western Reserve University
- Huvudutredare: Megan Allyse, PhD, Case Western Reserve University
Publikationer och användbara länkar
Allmänna publikationer
- Allyse MA, Sengupta S, Michie M. The Challenges of Reproductive Autonomy in an Unjust System. Am J Bioeth. 2025 Dec;25(12):67-69. doi: 10.1080/15265161.2025.2570681. Epub 2025 Nov 18. No abstract available.
- Allyse M, Riggan K, Bonhomme N, Michie M. Rethinking the Burden of Traditional Informed Consent Prior to Prenatal Genetic Screening. Hastings Cent Rep. 2025 Mar;55(2):29-38. doi: 10.1002/hast.4976.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- STUDY20251580
- R01HG013718 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Data will be shared via the Inter-university Consortium for Political and Social Research. To the extent the context of data collection can be revealed without compromising the privacy and identity of research participants, it will be included in study protocols. Data will be anonymized.
Qualitative data such as de-identified and redacted transcripts, coding summaries, and metadata will be shared. Quantitative, including de-identified individual and aggregate survey data (including raw and recoded data) will be shared.
Tidsram för IPD-delning
Approximately six to twelve months after the completion of data analysis. Methods and data collection instruments will be available to the research community before the completion of the study. Published outcomes as well as data deposited in the Inter-university Consortium for Political and Social Research will be available indefinitely.
Kriterier för IPD Sharing Access
Access to all deposited materials will be available to researchers registered and verified through the Inter-university Consortium for Political and Social Research (ICPSR). The ICPSR, a digital repository, utilizes a "Reference Model for an Open Archival Information System (OAIS), an International Organization for Standardization (ISO) standard that provides the functional framework for sustaining digital objects in managed repositories." Detailed access criteria can be found here: https://www.icpsr.umich.edu/sites/icpsr/about/policies/access-policy-framework
IPD-delning som stöder informationstyp
- SAV
- ICF
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .